Evaluate the Effects of Dapagliflozin in Patients With Type 2 Diabetes

  • days left to enroll
  • participants needed
  • sponsor
    Centre Hospitalier Universitaire Dijon
Updated on 23 January 2021


This study will make it possible to better understand the mechanisms responsible for the increase in bad cholesterol levels observed in patients with type 2 diabetes treated with Dapagliflozin, an antidiabetic treatment made by Astrazeneca.

The information will:

  • reveal what is not working properly
  • make it possible to choose the most appropriate treatments against cholesterol to compensate for this impaired functioning

This biomedical research will take place at the University Hospitals of DIJON and NANTES.

  • 28 patients will take part: 20 patients will be given Dapagliflozin and 8 patients will be given the placebo.
  • The study treatment will be randomised: patients will be given either Dapagliflozin or the placebo. The treatment duration is 6 months.
  • Moreover, during the inclusion visit and at the end of the study (6 months after the start of treatment), a kinetics study, to follow the production and elimination of cholesterol, will be conducted. This will involve administering amino acids that have been specifically synthesised for this purpose.
  • Participation in the study will last 6 months and include 4 protocol visits.

Condition NIDDM, Diabetes Mellitus, Diabetes Mellitus, Type 2, Diabetes Prevention, Diabetes Mellitus Types I and II, Diabetes (Pediatric), Diabetes Mellitus Type 2, Oral Antidiabetics, type 2 diabetes mellitus, type 2 diabetes, type ii diabetes, noninsulin-dependent diabetes mellitus, diabetes type 2
Treatment placebos, Dapagliflozin
Clinical Study IdentifierNCT03269058
SponsorCentre Hospitalier Universitaire Dijon
Last Modified on23 January 2021


Yes No Not Sure

Inclusion Criteria

Is your age between 30 yrs and 65 yrs?
Gender: Male or Female
Do you have any of these conditions: NIDDM or Oral Antidiabetics?
Do you have any of these conditions: diabetes type 2 or Diabetes Mellitus Types I and II or NIDDM or Diabetes (Pediatric) or type 2 diabetes or Diabetes Mellitus Type 2 or type 2 diabetes...?
persons who have provided written consent
type 2 diabetes treated with OAD (metformin and/or sulfonylurea and/or glinides and/or acarbose and/or DPPIV inhibitors)
Stable treatment for 3 months
HbA1c between 7.5% and 10%
Age between 30 and 65 years
BMI between 25 and 35 kg/m
Triglycerides < 300 mg/dl
Half of the patients being treated with statins
eGFR > 75 ml/min/1.73 m at inclusion

Exclusion Criteria

persons without national health insurance cover
patients treated with Insulin or a GLP-1 agonist
Patients under guardianship
patients treated with lipid-lowering drugs (except statins for 50% of patients)
kidney failure
liver failure or abnormal liver function ASAT or ALAT >3 x upper limit of normal
total bilirubin >2mg/dl
intestinal disease
serological evidence of an active liver infection (surface antigen of hepatitis B, hepatitis C antibodies, hepatitis B IgM antibodies)
Pregnancy, breastfeeding
hypersensitivity to the active substance or to excipients
patients with volume depletion, for example due to an acute disease (gastro-intestinal disease)
patients treated with loop diuretics or thiazides
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Phone Email

Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note